Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2021 | Patient perspective: UK approval of first-line brigatinib

Debra Montague • 19 Apr 2021
BTOG 2021
Lung Cancer Non-Small Cell Lung Cancer Brigatinib

Debra Montague, Founder & Chairman, ALK Positive UK, discusses the NICE approval of brigatinib in the first line in the UK for the treatment of patients with ALK-positive lung cancer who have previously been treated with an ALK inhibitor. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

More from Debra Montague

2:17
Lung cancer patient experience in the UK
Debra Montague • 19 Apr 2021
4:31
Activities of ALK Positive UK
Debra Montague • 19 Apr 2021
2:37
Being a patient with lung cancer during the COVID-19 pandemic
Debra Montague • 19 Apr 2021

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals